Next Article in Journal
Regulation of Adipogenesis by Quinine through the ERK/S6 Pathway
Next Article in Special Issue
Prevalence and Predictors of Clozapine-Associated Constipation: A Systematic Review and Meta-Analysis
Previous Article in Journal
Beyond the Niche: Myelodysplastic Syndrome Topobiology in the Laboratory and in the Clinic
Previous Article in Special Issue
Aripiprazole and Haloperidol Activate GSK3β-Dependent Signalling Pathway Differentially in Various Brain Regions of Rats
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2016, 17(4), 551; doi:10.3390/ijms17040551

Is There Room for Second-Generation Antipsychotics in the Pharmacotherapy of Panic Disorder? A Systematic Review Based on PRISMA Guidelines

1
Department of Clinical Neurosciences, Hermanas Hospitalarias, Villa San Benedetto Menni Hospital, FoRiPsi, via Roma 16, Albese con Cassano, 22032 Como, Italy
2
Department of Psychiatry and Neuropsychology, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6200 Maastricht, The Netherlands
3
Department of Psychiatry and Behavioral Sciences, Leonard Miller School of Medicine, Miami University, Miami, FL 33136, USA
4
Child Psychopathology Unit, Scientific Institute, IRCCS Eugenio Medea, Bosisio Parini, 23842 Lecco, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Domenico De Berardis
Received: 23 February 2016 / Revised: 31 March 2016 / Accepted: 6 April 2016 / Published: 13 April 2016
(This article belongs to the Special Issue Antipsychotics)
View Full-Text   |   Download PDF [636 KB, uploaded 25 April 2016]   |  

Abstract

A role for second-generation antipsychotics (SGAs) in the treatment of panic disorders (PD) has been proposed, but the actual usefulness of SGAs in this disorder is unclear. According to the PRISMA guidelines, we undertook an updated systematic review of all of the studies that have examined, in randomized controlled trials, the efficacy and tolerability of SGAs (as either monotherapy or augmentation) in the treatment of PD, with or without other comorbid psychiatric disorders. Studies until 31 December 2015 were identified through PubMed, PsycINFO, Embase, Cochrane Library and Clinical trials.gov. Among 210 studies, five were included (two involving patients with a principal diagnosis of PD and three involving patients with bipolar disorder with comorbid PD or generalized anxiety disorder). All were eight-week trials and involved treatments with quetiapine extended release, risperidone and ziprasidone. Overall, a general lack of efficacy of SGAs on panic symptoms was observed. Some preliminary indications of the antipanic effectiveness of risperidone are insufficient to support its use in PD, primarily due to major limitations of the study. However, several methodological limitations may have negatively affected all of these studies, decreasing the validity of the results and making it difficult to draw reliable conclusions. Except for ziprasidone, SGAs were well tolerated in these short-term trials. View Full-Text
Keywords: panic disorder; second-generation antipsychotics; quetiapine; risperidone; ziprasidone; bipolar disorder panic disorder; second-generation antipsychotics; quetiapine; risperidone; ziprasidone; bipolar disorder
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Perna, G.; Alessandra, A.; Raffaele, B.; Elisa, M.; Giuseppina, D.; Paolo, C.; Maria, N.; Daniela, C. Is There Room for Second-Generation Antipsychotics in the Pharmacotherapy of Panic Disorder? A Systematic Review Based on PRISMA Guidelines. Int. J. Mol. Sci. 2016, 17, 551.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top